Quick Answer
Addex Therapeutics Ltd. reported R&D Expense of $854.3 thousand for fiscal year 2024.
Addex Therapeutics Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2024 | $854.3K | -28.0% |
| 2023 | $1.19M | -85.6% |
| 2022 | $8.24M | -35.8% |
| 2021 | $12.84M | +23.8% |
| 2020 | $10.37M | -16.7% |
| 2019 | $12.45M | +153.2% |
| 2018 | $4.92M | +87.1% |
| 2017 | $2.63M | — |
- Addex Therapeutics Ltd. showed a decrease of -28.0% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2024 period, Addex Therapeutics Ltd.’s r&d expense has declined by 67.5% (from $2.63 million to $854.3 thousand).
- The most recent figure is from Addex Therapeutics Ltd.’s fiscal year 2024 report (Form 20-F), filed with the SEC on May 15, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: